Clinical Trial Update: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

View source ↗

Summary

A follow-up study evaluating the long-term safety and tolerability of the AD03 immunization used during AFF005A for Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AD03 (AD03)

Snippet

Sponsor: Affiris AG | Conditions: Alzheimer's Disease | Status: TERMINATED